Therapeutic approaches to innate immunity: severe sepsis and septic shock

[1]  N. H. Steigbigel.  Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock , 2003, Current infectious disease reports.

[2]  L. Leng,et al.  MIF Signal Transduction Initiated by Binding to CD74 , 2003, The Journal of experimental medicine.

[3]  J. Marshall,et al.  Such stuff as dreams are made on: mediator-directed therapy in sepsis , 2003, Nature Reviews Drug Discovery.

[4]  D. Mannino,et al.  The epidemiology of sepsis in the United States from 1979 through 2000. , 2003, The New England journal of medicine.

[5]  R. Gazzinelli.  Faculty Opinions recommendation of Cutting edge: a Toll-like receptor 2 polymorphism that is associated with lepromatous leprosy is unable to mediate mycobacterial signaling. , 2003 .

[6]  S. Opal,et al.  A New Paradigm for the Treatment of Sepsis: Is It Time To Consider Combination Therapy? , 2003, Annals of Internal Medicine.

[7]  A. Al-ghonaium,et al.  Pyogenic Bacterial Infections in Humans with IRAK-4 Deficiency , 2003, Science.

[8]  Siamon Gordon,et al.  Pattern Recognition Receptors Doubling Up for the Innate Immune Response , 2002, Cell.

[9]  Jonathan Cohen.  The immunopathogenesis of sepsis , 2002, Nature.

[10]  K. Tracey,et al.  HMGB1 as a cytokine and therapeutic target , 2002, Journal of endotoxin research.

[11]  Charles Natanson,et al.  Risk and the efficacy of antiinflammatory agents: retrospective and confirmatory studies of sepsis. , 2002, American journal of respiratory and critical care medicine.

[12]  K. Tracey,et al.  Ethyl pyruvate prevents lethality in mice with established lethal sepsis and systemic inflammation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[13]  Elias Lolis,et al.  The Tautomerase Active Site of Macrophage Migration Inhibitory Factor Is a Potential Target for Discovery of Novel Anti-inflammatory Agents* , 2002, The Journal of Biological Chemistry.

[14]  John D Lambris,et al.  Increased C5a receptor expression in sepsis. , 2002, The Journal of clinical investigation.

[15]  D. Schwartz,et al.  Relevance of mutations in the TLR4 receptor in patients with gram-negative septic shock. , 2002, Archives of internal medicine.

[16]  R. Bucala,et al.  Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity. , 2002, Journal of medicinal chemistry.

[17]  P. Gregersen,et al.  A functional promoter polymorphism in the macrophage migration inhibitory factor (MIF) gene associated with disease severity in rheumatoid arthritis , 2002, Genes and Immunity.

[18]  J. Vincent,et al.  Clinical trials of immunomodulatory therapies in severe sepsis and septic shock. , 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[19]  E. Cua,et al.  Anticorps anti-TNFα (infliximab) et tuberculose :à propos de trois cas , 2002 .

[20]  Y. Ogura,et al.  Nods: a family of cytosolic proteins that regulate the host response to pathogens. , 2002, Current opinion in microbiology.

[21]  Peter D. Senter,et al.  Inhibition of macrophage migration inhibitory factor (MIF) tautomerase and biological activities by acetaminophen metabolites , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[22]  John David,et al.  Macrophage migration inhibitory factor (MIF) sustains macrophage proinflammatory function by inhibiting p53: Regulatory role in the innate immune response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[23]  T. Calandra,et al.  MIF regulates innate immune responses through modulation of Toll-like receptor 4 , 2001, Nature.

[24]  G. Cooke,et al.  Genetics of susceptibitlity to human infectious disease , 2001, Nature Reviews Genetics.

[25]  E. Ivers,et al.  Early Goal-Directed Therapy in the Treatment of Severe Sepsis and Septic Shock , 2001 .

[26]  R. Bucala,et al.  Mechanisms for modulating TNF alpha in immune and inflammatory disease. , 2001, Current opinion in drug discovery & development.

[27]  C. Esmon,et al.  Dysfunction of endothelial protein C activation in severe meningococcal sepsis. , 2001, The New England journal of medicine.

[28]  G. Clermont,et al.  Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care , 2001, Critical care medicine.

[29]  K. Reinhart,et al.  Anti-tumor necrosis factor therapy in sepsis: Update on clinical trials and lessons learned , 2001, Critical care medicine.

[30]  L. Thijs,et al.  Macrophage migration inhibitory factor and hypothalamo-pituitary-adrenal function during critical illness. , 2001, The Journal of clinical endocrinology and metabolism.

[31]  Ó. N. Martínez,et al.  Reactivation tuberculosis in a patient with anti–TNF-α treatment , 2001, American Journal of Gastroenterology.

[32]  M. Matthay.  Severe sepsis--a new treatment with both anticoagulant and antiinflammatory properties. , 2001, The New England journal of medicine.

[33]  J Ean,et al.  Efficacy and safety of recombinant human activated protein C for severe sepsis. , 2001, The New England journal of medicine.

[34]  E. Abraham.  Tissue factor inhibition and clinical trial results of tissue factor pathway inhibitor in sepsis. , 2000, Critical care medicine.

[35]  A. Aderem,et al.  Toll-like receptors in the induction of the innate immune response , 2000, Nature.

[36]  K. Acharya,et al.  Microbial superantigens: from structure to function. , 2000, Trends in microbiology.

[37]  E. Van Obberghen,et al.  SOCS-3 Is an Insulin-induced Negative Regulator of Insulin Signaling* , 2000, The Journal of Biological Chemistry.

[38]  M. Colonna,et al.  Cutting Edge: Inflammatory Responses Can Be Triggered by TREM-1, a Novel Receptor Expressed on Neutrophils and Monocytes1 , 2000, The Journal of Immunology.

[39]  J. A. Kruse,et al.  E5 murine monoclonal antiendotoxin antibody in gram-negative sepsis: a randomized controlled trial. E5 Study Investigators. , 2000, JAMA.

[40]  C. Esmon.  Regulation of blood coagulation. , 2000, Biochimica et biophysica acta.

[41]  D. Annane,et al.  A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. , 2000, JAMA.

[42]  R. Bucala,et al.  Protection from septic shock by neutralization of macrophage migration inhibitory factor , 2000, Nature Medicine.

[43]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[44]  Douglas M. Call,et al.  Immunopathologic Alterations in Murine Models of Sepsis of Increasing Severity , 1999, Infection and Immunity.

[45]  Michael Bustin,et al.  Regulation of DNA-Dependent Activities by the Functional Motifs of the High-Mobility-Group Chromosomal Proteins , 1999, Molecular and Cellular Biology.

[46]  K. Tracey,et al.  HMG-1 as a late mediator of endotoxin lethality in mice. , 1999, Science.

[47]  P. Ward,et al.  Protective effects of C5a blockade in sepsis , 1999, Nature Medicine.

[48]  W. Johnson,et al.  Crystal structure of macrophage migration inhibitory factor complexed with (E)-2-fluoro-p-hydroxycinnamate at 1.8 A resolution: implications for enzymatic catalysis and inhibition. , 1999, Biochemistry.

[49]  E. Abraham,et al.  Why immunomodulatory therapies have not worked in sepsis , 1999, Intensive Care Medicine.

[50]  KlasMalmberg,et al.  Glycometabolic State at Admission: Important Risk Marker of Mortality in Conventionally Treated Patients With Diabetes Mellitus and Acute Myocardial Infarction , 1999 .

[51]  E Lolis,et al.  Pro-1 of macrophage migration inhibitory factor functions as a catalytic base in the phenylpyruvate tautomerase activity. , 1999, Biochemistry.

[52]  T. Nakamura,et al.  Treatment with polymyxin B-immobilized fiber reduces platelet activation in septic shock patients: Decrease in plasma levels of soluble P-selectin, platelet factor 4 and β-thromboglobulin , 1999, Inflammation Research.

[53]  A. Satoskar,et al.  Targeted Disruption of Migration Inhibitory Factor Gene Reveals Its Critical Role in Sepsis , 1999, The Journal of experimental medicine.

[54]  T. Nakamura,et al.  Effect of hemoperfusion with polymyxin B-immobilized fiber on plasma endothelin-1 and endothelin-1 mRNA in monocytes from patients with sepsis. , 1998, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[55]  D. Annane,et al.  Impaired pressor sensitivity to noradrenaline in septic shock patients with and without impaired adrenal function reserve. , 1998, British journal of clinical pharmacology.

[56]  R. Bucala,et al.  Macrophage migration inhibitory factor is a critical mediator of the activation of immune cells by exotoxins of Gram-positive bacteria. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[57]  I. Ebihara,et al.  Hemoperfusion with Polymyxin B- Immobilized Fiber Attenuates the Increased Plasma Levels of Thrombomodulin and von Willebrand Factor from Patients with Septic Shock , 1998, Blood Purification.

[58]  Hong-Wei Sun,et al.  Direct link between cytokine activity and a catalytic site for macrophage migration inhibitory factor , 1998, The EMBO journal.

[59]  W. Sibbald,et al.  Polymyxin-dextran antiendotoxin pretreatment in an ovine model of normotensive sepsis. , 1997, Critical care medicine.

[60]  S. Targan,et al.  A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease , 1997 .

[61]  C. Natanson,et al.  Anti-inflammatory therapies to treat sepsis and septic shock: a reassessment. , 1997, Critical care medicine.

[62]  K. Malmberg.  Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus , 1997, BMJ.

[63]  P. Peduzzi,et al.  Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group. , 1997, JAMA.

[64]  T. van der Poll,et al.  Interleukin-6 Stimulates Coagulation, not Fibrinolysis, in Humans , 1996, Thrombosis and Haemostasis.

[65]  S. Opal,et al.  Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group. , 1996, The New England journal of medicine.

[66]  J. Bernhagen,et al.  Crystal structure at 2.6-A resolution of human macrophage migration inhibitory factor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[67]  F. Stüber,et al.  A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. , 1996, Critical care medicine.

[68]  Atsushi Nakagawa,et al.  Crystal structure of the macrophage migration inhibitory factor from rat liver , 1996, Nature Structural Biology.

[69]  J. Bernhagen,et al.  MIF as a glucocorticoid-induced modulator of cytokine production , 1995, Nature.

[70]  D. Cook,et al.  Corticosteroid treatment for sepsis: a critical appraisal and meta-analysis of the literature. , 1995, Critical care medicine.

[71]  L. Moldawer,et al.  BLOCKADE OF TUMOR NECROSIS FACTOR REDUCES LIPOPOLYSACCHARIDE LETHALITY, BUT NOT THE LETHALITY OF CECAL LIGATION AND PUNCTURE , 1995, Shock.

[72]  R. Wenzel,et al.  Long-term survival and function after suspected gram-negative sepsis. , 1995, JAMA.

[73]  S. Bucklin,et al.  Therapeutic efficacy of a polymyxin B-dextran 70 conjugate in experimental model of endotoxemia , 1995, Antimicrobial agents and chemotherapy.

[74]  R. Lefering,et al.  Steroid controversy in sepsis and septic shock: a meta-analysis. , 1995, Critical care medicine.

[75]  N. MacIntyre,et al.  A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group. , 1995, Critical care medicine.

[76]  S. Lamberts,et al.  Differential adaptation of glucocorticoid sensitivity of peripheral blood mononuclear leukocytes in patients with sepsis or septic shock. , 1995, The Journal of clinical endocrinology and metabolism.

[77]  D. Pittet,et al.  The natural history of the systemic inflammatory response syndrome (SIRS). A prospective study. , 1995, JAMA.

[78]  M. Poncz,et al.  Structural requirements of platelet chemokines for neutrophil activation. , 1994, Blood.

[79]  Craig R. Smith,et al.  Treatment of Septic Shock with Human Monoclonal Antibody HA-1A , 1994, Annals of Internal Medicine.

[80]  K. Tracey,et al.  MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia , 1993, Nature.

[81]  C. Dinarello,et al.  The role of interleukin-1 in disease. , 1993, The New England journal of medicine.

[82]  J. Cavaillon,et al.  Assessment of ability of murine and human anti-lipid A monoclonal antibodies to bind and neutralize lipopolysaccharide , 1993, The Journal of experimental medicine.

[83]  W. Knaus,et al.  Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. , 1992, Chest.

[84]  D. Remick,et al.  Anti-tumor necrosis factor antibody therapy fails to prevent lethality after cecal ligation and puncture or endotoxemia. , 1992, Journal of immunology.

[85]  M. A. Martin,et al.  A controlled clinical trial of E5 murine monoclonal IgM antibody to endotoxin in the treatment of gram-negative sepsis. The XOMA Sepsis Study Group. , 1991, JAMA.

[86]  Jerome J. Schentag,et al.  A Controlled Clinical Trial of E5 Murine Monoclonal IgM Antibody to Endotoxin in the Treatment of Gram-Negative Sepsis , 1991 .

[87]  C. Esmon,et al.  Inflammation and Coagulation: Linked Processes Potentially Regulated Through a Common Pathway Mediated by Protein C , 1991, Thrombosis and Haemostasis.

[88]  B. Echtenacher,et al.  Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. , 1990, Journal of immunology.

[89]  J. Weinberg,et al.  Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line U937 and peripheral blood monocytes. , 1988, Blood.

[90]  R. Wolfe,et al.  Effect of severe burn injury on substrate cycling by glucose and fatty acids. , 1987, The New England journal of medicine.

[91]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[92]  W. Fiers,et al.  Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: characterization and comparison with the actions of interleukin 1. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[93]  J. McCutchan,et al.  PREVENTION OF GRAM-NEGATIVE SHOCK AND DEATH IN SURGICAL PATIENTS BY ANTIBODY TO ENDOTOXIN CORE GLYCOLIPID , 1985, The Lancet.

[94]  J. McCutchan,et al.  TREATMENT OF GRAM-NEGATIVE BACTEREMIA AND SHOCK WITH HUMAN ANTISERUM TO A MUTANT ESCHERICHIA COLI , 1983 .

[95]  Jean-Guy Cyr,et al.  Principles and Practice of Infectious Diseases , 1980 .

[96]  J. Oppenheimer,et al.  A Reassessment , 1979 .

[97]  R L Kassel,et al.  An endotoxin-induced serum factor that causes necrosis of tumors. , 1975, Proceedings of the National Academy of Sciences of the United States of America.

[98]  G. Richards,et al.  The epidemiology of sepsis. , 1973, Clinical orthopaedics and related research.

[99]  B. Waksman,et al.  Cytotoxic Effect of Lymphocyte-Antigen Interaction in Delayed Hypersensitivity , 1967, Science.

[100]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[101]  G. Beldi,et al.  A prospective, randomized clinical trial , 2004 .

[102]  B. Bistrian,et al.  Intensive insulin therapy in critically ill patients. , 2002, The New England journal of medicine.

[103]  G. V. Poole,et al.  Trauma patients with positive cultures have higher levels of circulating macrophage migration inhibitory factor (MIF). , 2000, Research communications in molecular pathology and pharmacology.

[104]  S. Targan,et al.  A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. , 1997, The New England journal of medicine.

[105]  M. Glauser,et al.  Anticytokine strategies for the treatment of septic shock: relevance of animal models. , 1996, Current topics in microbiology and immunology.

[106]  B A Mizock,et al.  Alterations in carbohydrate metabolism during stress: a review of the literature. , 1995, The American journal of medicine.

[107]  R. Straube,et al.  Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group. , 1994, Annals of internal medicine.

[108]  R. Dellinger,et al.  Treatment of gram-negative septic shock with an immunoglobulin preparation: a prospective, randomized clinical trial. , 1993, Critical care medicine.

[109]  J. J. Thompson,et al.  Divergent efficacy of antibody to tumor necrosis factor-alpha in intravascular and peritonitis models of sepsis. , 1991, The Journal of infectious diseases.

[110]  John E. Bennett,et al.  Principles and practice of infectious diseases. Vols 1 and 2. , 1979 .

[111]  R. Segurado,et al.  A Randomized Controlled Trial , 2022 .

[112]  J. E. Barone,et al.  A Meta-Analysis , 2022 .